CompletedPhase 1NCT04421677
Safety and Tolerability of Phenylbutyrate in Inclusion Body Myositis
Studying Inclusion body myositis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of Kansas Medical Center
- Principal Investigator
- Duaa Jabari, MD, MDUniversity of Kansas Medical Center
- Intervention
- Phenylbutyrate Oral Tablet(drug)
- Enrollment
- 10 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2020 – 2022
Study locations (1)
- University of Kansas Medical Center, Kansas City, Kansas, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04421677 on ClinicalTrials.govOther trials for Inclusion body myositis
Additional recruiting or active studies for the same condition.
- ENROLLING BY INVITATIONNANCT07072676The Use of Assistive Gait Devices Can Reduce the Risk of Falls in Patients With Neuromuscular Diseases Following a Training Period.LMU Klinikum
- RECRUITINGPHASE2NCT06536166Ruxolitinib Treatment in Inclusion Body MyositisAssistance Publique - Hôpitaux de Paris
- ACTIVE NOT RECRUITINGPHASE2, PHASE3NCT06450886Long-term Extension Study of Ulviprubart (ABC008) in Subjects With Inclusion Body MyositisAbcuro, Inc.
- RECRUITINGEARLY PHASE1NCT06479863Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients With Sporadic Inclusion Body MyositisAustin Neuromuscular Center
- ACTIVE NOT RECRUITINGNCT06153108Monitoring Biomarker for Detecting Change in Physical Activity and Limb Function in Inclusion Body Myositis Over TimeUniversity of Kansas Medical Center
- ACTIVE NOT RECRUITINGPHASE3NCT04789070Phase III Trial of Sirolimus in IBMUniversity of Kansas Medical Center
- ACTIVE NOT RECRUITINGNCT05046821Sporadic Inclusion Body Myositis Natural History StudyUniversity of California, Irvine